Table 10 The barriers to implement PV and ADR reporting (n = 342)
Statement | Level of agreement, n (%) | Median (IQR) scores | ||||
|---|---|---|---|---|---|---|
| Â | Strongly Disagree (1) | Disagree (2) | Neutral (3) | Agree (4) | Strongly Agree (5) | Â |
1. It is not a part of pharmacist’s job | 159 (46.5) | 122 (35.7) | 22 (6.4) | 27 (7.9) | 12 (3.5) | 2 (1–2) |
2. Lack of awareness about the reporting process | 7 (2.1) | 33 (9.7) | 38 (11.1) | 195 (57) | 69 (20.2) | 4 (4–4) |
3. All serious ADRs are already detected before registration of drug | 63 (18.4) | 157 (45.9) | 65 (19) | 45 (13.2) | 12 (3.5) | 2 (2–3) |
4. Fear of consequences after reporting (i.e., legal actions or reduced patient’s confidence) | 12 (3.5) | 51 (14.9) | 63 (18.4) | 169 (49.4) | 47 (13.7) | 4 (3–4) |
5. Lack of awareness of the existence of a national ADR reporting system | 9 (2.6) | 32 (9.4) | 30 (8.8) | 176 (51.5) | 95 (27.8) | 4 (4–5) |
6. Pharmacovigilance topic not included in pharmacy curriculum | 27 (7.9) | 113 (33) | 61 (17.8) | 93 (27.2) | 48 (14) | 3 (2–4) |
7. Lack of proper training on ADR reporting | 12 (3.5) | 30 (8.8) | 28 (8.2) | 169 (49.4) | 103 (30.1) | 4 (4–5) |
8. Difficulty in deciding whether ADR had occurred or not | 25 (7.3) | 71 (20.8) | 70 (20.5) | 129 (37.7) | 47 (13.7) | 4 (2–4) |